Macquarie Group’s Protara Therapeutics TARA Stock Holding History

Macquarie Group’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-333	Closed	-$8K	–	2400
2020 Q1	$8K	Buy	+333	New	+$9.7K	﹤0.01%	1943
2018 Q1	–	Sell	-85	Closed	-$6K	–	2352
2017 Q4	$6K	Buy	+85	New	+$6.82K	﹤0.01%	2339

Other funds holding TARA

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's TARA Position: Q2 2020 in Review

Macquarie Group sold out of Protara Therapeutics (TARA) in Q2 2020, closing a stake of 333 shares — an estimated $8K sold.

Macquarie Group first reported a position in TARA in Q4 2017 and held it in 2 quarters. The position peaked at $8K in Q1 2020. 33 funds tracked by Wall St. Rank hold TARA as of Q2 2020.

Macquarie Group reported no remaining Protara Therapeutics position as of Q2 2020 after selling out during the quarter.
Macquarie Group sold 333 Protara Therapeutics shares in Q2 2020, an estimated $8K.
Macquarie Group first reported a position in Protara Therapeutics in Q4 2017 and held it in 2 quarters.
Macquarie Group's Protara Therapeutics position peaked at $8K in Q1 2020.
33 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2020.

Based on Macquarie Group's 13F filing for Q2 2020, filed 11 Aug 2020.